Loading...
Market
How many additional indications will Tecentriq Hybreza receive FDA approval for by the end of 2025?
2
Resolution / Starting Odds
None • 25%
1 additional indication • 25%
2 additional indications • 25%
3 or more additional indications • 25%
FDA approval announcements
Story
FDA Approves Genentech’s Tecentriq Hybreza, First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy $RHHBY
Sep 12, 2024, 09:30 PM
The FDA has approved Genentech's Tecentriq Hybreza, making it the first subcutaneous anti-PD-(L)1 cancer immunotherapy available in the U.S. This approval marks a significant step in cancer treatment, providing a more accessible option for patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma. Halozyme's ENHANZE technology played a crucial role in the development of this subcutaneous formulation. The stocks for Genentech ($RHHBY) and Halozyme ($HALO) are likely to be impacted by this approval.
View original story
Similar markets
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0 new indications • 33%
1 new indication • 33%
2 or more new indications • 34%
1-2 • 25%
3-4 • 25%
5-6 • 25%
More than 6 • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Less than 10 • 25%
10-20 • 25%
21-30 • 25%
More than 30 • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%